Safety and Efficacy of Vildagliptin Plus Metformin (SPC) Treatment in Type 2 Diabetes Mellitus Patients
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
This study will assess the efficacy of vildagliptin plus metformin (SPC) treatment in type 2
diabetes mellitus patients uncontrolled by metformin monotherapy after 24 weeks treatment